On Mar. 12, 2020, Vir Biotech announced it had signed a letter of intent with Biogen for the development and clinical manufacturing of human monoclonal antibodies for the potential treatment of COVID-19, the disease caused by the SARS-CoV-2 virus.

Because of the urgency of the situation, the companies began work while a Clinical Development and Manufacturing Agreement was being negotiated.